CoChat

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

Open access

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors. METHODS: We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor. We assessed antitumor response and the safety and tolerability of the drug. Pharmacokinetics were assessed in a subgroup of patients. RESULTS: A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily. Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for technical reasons, response could not be evaluated in 7 patients (4.8 percent). No patient had a complete response to the treatment. The median duration of response had not been reached after a median follow-up of 24 weeks after the onset of response. Early resistance to imatinib was noted in 20 patients (13.6 percent). Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common. Gastrointestinal or intraabdominal hemorrhage occurred in approximately 5 percent of patients. There were no significant differences in toxic effects or response between the two doses. Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia. CONCLUSIONS: Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa020461

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 21 references

Research works printed but not linked: 4

  1. Rubin BP, 2001, Cancer Res, 61, 8118
  2. Goss GA, 2000, Prog Proc Am Soc Clin Oncol, 19, 599a
  3. Buchdunger E, 2000, J Pharmacol Exp Ther, 295, 139
  4. Peng B, 2001, Prog Proc Am Soc Clin Oncol, 20, 71a

Cited by

Items 601–700 of 1,007

Metadata

Authors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., Fletcher, J. A., Silverman, S. G., Silberman, S. L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B. J., Corless, C., Fletcher, C. D. M., & Joensuu, H.
Affiliations
  • Harvard University (US)
  • Oregon Health & Science University (US)
  • Fox Chase Cancer Center (US)
  • Novartis (Switzerland) (CH)
  • University of Helsinki (FI)
Venue
New England Journal of Medicine
Published
2002-08-15
Volume
347
Issue
7
Pages
472-480
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2015015957
Cited by
4,389
References
21
Citations by year
2026: 85 · 2025: 91 · 2024: 107 · 2023: 115 · 2022: 117 · 2021: 128 · 2020: 136 · 2019: 119 · 2018: 131 · 2017: 136 · 2016: 160 · 2015: 182 · 2014: 192 · 2013: 210 · 2012: 255
FWCI
167.44
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • CRC Press eBooks (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Funders
  • U.S. Department of Veterans Affairs
  • Northwest Health Foundation
  • Helsingin Yliopisto
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Keywords
imatinib mesylate, gastrointestinal stromal tumor, KIT receptor tyrosine kinase, tyrosine kinase inhibitors, antitumor immunity, drug resistance, pharmacokinetics, adverse effects, metastatic cancer, dose comparison
MeSH terms
Imatinib Mesylate, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Benzamides, Female, Gastrointestinal Neoplasms, Humans, Male, Middle Aged, Piperazines, Protein-Tyrosine Kinases, Pyrimidines, Remission Induction, Signal Transduction, Survival Analysis, Stromal Cells, Proto-Oncogene Proteins c-kit

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.